To include your compound in the COVID-19 Resource Center, submit it here.

Fresh off Lilly deal, AbCellera readies to deploy $105M to streamline antibody-based R&D

Days after expanding a deal with Eli Lilly, AbCellera has raised $105 million in a series B round to speed its partners’ path to the clinic by expanding its own R&D capabilities.

CEO Carl Hansen told BioCentury that AbCellera Biologics Inc. will use the untranched round to “double down on capacity, on people and on

Read the full 543 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers